Wei Li

64.8k citations
1.3k papers · 52.8k · 21 hit papers · h-index 97

Impact in

    • Breast Cancer Treatment Studies
    • Cancer, Hypoxia, and Metabolism
  • Oncology top 0.2%
    • HER2/EGFR in Cancer Research

Papers in

Wei Li

1.3k papers receiving 51.7k citations

Wei Li's Hit Papers

Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial 2025 · 35 citations
350+3+6Years since publication5001k1.5k2k2.5k

Peers

Wei Li
Comparison fields: 5 of 173
  • Cancer Research 5.7k
  • Oncology 7.4k
  • Pulmonary and Respiratory Medicine 6.7k
  • Pathology and Forensic Medicine 3.6k
  • Molecular Biology 9.7k
Replace Lorenzo Galluzzi with:
Lorenzo Galluzzi France
Peter Vandenabeele Belgium
Navdeep S. Chandel United States
John C. Reed United States
Wafik S. El‐Deiry United States
Beth Levine United States
Napoleone Ferrara United States
Peng Huang China
Gautam Sethi Singapore
Scott Lowe United States
Wei Li relative to Lorenzo Galluzzi France Lorenzo Galluzzi's profile →
Citations per field
00.5×1.7×
Lorenzo Galluzzi · 1×
Citations per year

Countries citing papers authored by Wei Li

Since Specialization
Citations

This map shows the geographic impact of Wei Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Li more than expected).

Fields of papers citing papers by Wei Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Li. The network helps show where Wei Li may publish in the future.

Co-authors

The 25 scholars most cited alongside Wei Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wei Li Line = papers co-authored together Wei Li links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 1.3k papers — load more, or switch the sort, to bring in the rest.

#Work
1
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Hit paper breakdown →
20172591
2
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Hit paper breakdown →
20221933
3
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Hit paper breakdown →
20141738
4
HIF-1α pathway: role, regulation and intervention for cancer therapy
Hit paper breakdown →
20151572
5
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Hit paper breakdown →
2023728
6
An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site
Hit paper breakdown →
2012666
7
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Hit paper breakdown →
2022482
8
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Hit paper breakdown →
2017427
9 2011412
10 2015405
11 2009390
12
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Hit paper breakdown →
2016382
13
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
Hit paper breakdown →
2016377
14
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Hit paper breakdown →
2015363
15 2017356
16 2009347
17
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
Hit paper breakdown →
2021324
18 2013322
19
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
Hit paper breakdown →
2019298
20 2009279

About Wei Li

Wei Li is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Molecular Biology and Pathology and Forensic Medicine, having authored 1.3k papers that have together received 52.8k indexed citations. Recurring topics across this work include Synthesis and biological activity (71 papers), Lung Cancer Treatments and Mutations (62 papers), Vitamin D Research Studies (60 papers), MicroRNA in disease regulation (42 papers), Cell death mechanisms and regulation (40 papers), HER2/EGFR in Cancer Research (36 papers), Pharmacogenetics and Drug Metabolism (35 papers) and Nanoparticle-Based Drug Delivery (35 papers). The work is most often cited by research in Cancer Research (5.7k citations), Oncology (7.4k citations), Pulmonary and Respiratory Medicine (6.7k citations), Pathology and Forensic Medicine (3.6k citations) and Molecular Biology (9.7k citations). Wei Li has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Duane D. Miller, Andrzej T. Slominski, Robert Charles Tuckey, Tae‐Kang Kim, Jianjun Chen, Yan Lü, Zorica Janjetović, Jin Wang, Kangcheng Ruan and Binghe Xu. Their work appears in journals such as Journal of Medicinal Chemistry, Frontiers in Oncology, Journal of Biological Chemistry, PLoS ONE and Bioorganic & Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact